Company Overview and News


Add PFIZER
to your dashboard

Headline News

Why Are These 6 Dow Stocks Fairly Valued?: Part 4 Of 5

5h seekingalpha
The Dow Jones Industrial Average is at an all-time high, but here are six that are fairly valued. (199-0)

A KISS Dividend Strategy Worth 15% A Year

12h seekingalpha
Quantitative investing aims at making systematic investment decisions based on hard data. Quantitative models make the investment process: (42-0)

BRIEF-Pfizer reports 5.4 pct passive stake in Rhythm Pharmaceuticals - ‍​SEC filing

23h reuters
* Pfizer Inc reports 5.4 percent passive stake in Rhythm Pharmaceuticals Inc as of October 10, 2017 - ‍​SEC filing Source text: (bit.ly/2ywc5E7) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136) (16-0)

Dow Jones Industrial Average Hits 23,000. Now What? | InvestorPlace

2017-10-18 investorplace
On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue? (364-0)

Pfizer's Advil May Be Just the Thing for Sickly Reckitt - Bloomberg

2017-10-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (16-0)

iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High

2017-10-18 zacks
For investors seeking momentum, iShares U.S. Healthcare ETF (IYH - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 27.7% from its 52-week low price of $137.30/share. (23-0)

Reckitt CEO Focuses on Health, Looking Beyond Worst Year - Bloomberg

2017-10-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (69-0)

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

2017-10-17 marketwired
NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors. (152-0)

Your Daily Pharma Scoop: ACRX Second Chance, AERI Rhopressa Success, Aratana ENTYCE Launch

2017-10-16 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (396-1)

J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

2017-10-16 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its plaque psoriasis drug, Stelara for use in adolescents (12 years of age or older). The drug is approved for adults in this indication since 2009. (154-0)

Merck invests in diabetes through KalVista deal | BioPharma Dive

2017-10-16 biopharmadive
Merck took an interest in the small biotech's early-stage drug, seeing a potential complement to its diabetes portfolio. (16-0)

BRIEF-Pfizer presents results from Phase 2 study of investigational ALK-inhibitor lorlatinib

2017-10-16 reuters
* Pfizer presents full results from Phase 2 study of next-generation investigational ALK-inhibitor lorlatinib in ALK-positive and ROS1-positive advanced non-small cell lung cancer (16-0)

Are These The 6 Best Stocks In The Dow Jones Industrial Average? - Part 3 Of 5

2017-10-13 seekingalpha
The Dow Jones Industrial Average is at all-time highs, but how many of the 30 Dow stocks are overvalued? (299-0)

Panacea Biotec, MSF India oppose Pfizer’s pneumonia vaccine patent

2017-10-13 livemint
New Delhi: The grant of a patent to Pfizer Inc.’s pneumonia vaccine Prevenar 13 has been opposed by Indian vaccine maker Panacea Biotec Ltd and MSF (Médecins Sans Frontières) India, the local unit of Paris-based humanitarian aid organization. (16-0)

Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval

2017-10-13 seekingalpha
An FDA Ad Com recommended approval for ONCE’s gene therapy for biallelic RPE65-mediated inherited retinal disease. (693-2)

Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

2017-10-13 investorplace
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The lack of a reaction is understandable: Kite may not bring it the growth that it needs. But Gilead’s HCV business is slowing, so management must put its excess cash to good use. Kite could be the company that re-accelerates growth. (119-0)

Glaxo Finds a Rich Vein to Mine With Supercomputers - Bloomberg

2017-10-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (134-0)

NIH partners 11 drugmakers to accelerate cancer therapy research

2017-10-12 reuters
(Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body’s immune system to fight cancer. (251-0)

Antacids Market Worth US $18.7 Billion by the End of 2025 Globally: Transparency Market Research

2017-10-12 prnewswire
"Considering the changing dietary habits and growing geriatric population worldwide, the global antacids market is anticipated to be on the rise in the upcoming years," explains a TMR analyst. As per statistics of the Asian Development Bank, the population of individuals above the age of 60 years in Asia is projected to touch 923 million by 2050. The elderly population that is more susceptible to gastroesophageal reflux diseases (GERD) and peptic ulcers is anticipated to account for significant demand for antacids in the region. (195-1)

Corporate News Blog - Pharma Giant Pfizer Mulling Divestment of Consumer Healthcare Business

2017-10-12 accesswire
LONDON, UK / ACCESSWIRE / October 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Pfizer Inc. (NYSE: PFE), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=PFE. The Company announced on October 10, 2017, that it is considering strategic alternatives for its Consumer Healthcare business. (87-0)

Researchers and Advocates Honored for Pioneering Efforts to End Lupus

2017-10-12 prnewswire
Global Ambassador Julian Lennon and Entertainer Whoopi Goldberg Open Lupus Foundation of America's Evening of Hope Gala (272-3)

Merck says will not seek approval of cholesterol treatment

2017-10-11 reuters
(Reuters) - Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings. (31-0)

U.S. Supreme Court May Shield Companies From Human-Rights Lawsuits - Bloomberg

2017-10-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (29-0)

Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study

2017-10-11 zacks
The series of setbacks continues for Eli Lilly and Company (LLY - Free Report) as the company announced that its phase III JUNIPER study failed to meet the primary endpoint. The study was evaluating Verzenio in advanced non-small lung cancer ("NSCLC") with KRAS mutation. Shares fell 1% on Tuesday after the announcement. (27-0)

Allergan Bulls Should Brace Themselves For Generic Restasis

2017-10-11 seekingalpha
Judge Bryson wants AGN to prove the Mohawks should be party to the federal patent litigation. (108-0)